{
    "title": "112_hr6584",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Verifying Authority and Legality In \nDrug Compounding Act of 2012''.\n\nSEC. 2. APPLICATION OF FEDERAL LAW TO PRACTICE OF PHARMACY COMPOUNDING.\n\n    (a) Amendment.--Section 503A of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 353a) is amended to read as follows:\n\n``SEC. 503A. PHARMACY COMPOUNDING.\n\n    ``(a) In General.--Sections 501(a)(2)(B) and 505 shall not apply \nwith respect to a drug product if each of the following applies:\n            ``(1) The drug product is compounded for an identified \n        individual patient based on the receipt of--\n                    ``(A) a valid prescription order; or\n                    ``(B) a notation, approved by the prescribing \n                practitioner, on the prescription order that a \n                compounded product is necessary for the identified \n                patient.\n            ``(2) The drug product is compounded by a licensed \n        pharmacist in a State-licensed pharmacy or a Federal facility, \n        or by a licensed physician, pursuant to such prescription order \n        or notation.\n            ``(3) The drug product is compounded exclusively from--\n                    ``(A) ingredients that comply with the standards of \n                an applicable United States Pharmacopoeia or National \n                Formulary monograph; or\n                    ``(B) if such a monograph does not exist, \n                ingredients that are ingredients in a drug--\n                            ``(i) for which an approval of an \n                        application filed under subsection (b) or (j) \n                        of section 505 is in effect; or\n                            ``(ii) that may be lawfully marketed in the \n                        United States without such an approval pursuant \n                        to the definition of a new drug in section 201.\n            ``(4) Any bulk substance used for purposes of compounding \n        the drug product--\n                    ``(A) is manufactured by an establishment that is \n                registered under section 510 (including a foreign \n                establishment that is registered under section 510(i)); \n                and\n                    ``(B) is accompanied by valid certificates of \n                analysis.\n            ``(5) The pharmacist or physician compounding the drug \n        product complies with the standards of any applicable United \n        States Pharmacopoeia chapters on pharmacy compounding.\n            ``(6) The drug product, including the dosage form and any \n        ingredient thereof, is not included in the list under \n        subsection (b).\n            ``(7) The drug product is not a copy of a commercially \n        available drug.\n    ``(b) List of Drug Products That Should Not Be Compounded.--\n            ``(1) In general.--For purposes of subsection (a)(6), the \n        Secretary shall--\n                    ``(A) develop and maintain a list of drug products \n                that should not be compounded, including any \n                categories, dosage forms, or ingredients of such drug \n                products; and\n                    ``(B) include on such list, at a minimum--\n                            ``(i) drug products (or categories, dosage \n                        forms, or ingredients thereof) whose \n                        compounding is reasonably likely to cause an \n                        adverse effect on safety or effectiveness of \n                        such drug product; and\n                            ``(ii) drug products (or categories, dosage \n                        forms, or ingredients thereof) that have been \n                        withdrawn or removed from the market because \n                        they have been found to be unsafe or not \n                        effective.\n            ``(2) Initial publication; updates.--The Secretary shall--\n                    ``(A) not later than 1 year after the date of the \n                enactment of the Verifying Authority and Legality In \n                Drug Compounding Act of 2012, publish an initial list \n                under paragraph (1); and\n                    ``(B) not less frequently than every year \n                thereafter, review and, as appropriate, update the list \n                under paragraph (1).\n            ``(3) Availability.--The Secretary shall make the list \n        under paragraph (1) available on the public Web site of the \n        Food and Drug Administration.\n            ``(4) Transmission to state regulatory agencies.--Upon \n        publication of the initial list under paragraph (1), and upon \n        each update to the list, the Secretary shall transmit an up-to-\n        date copy of the list to the agency in each State with primary \n        responsibility for regulating the compounding of drugs.\n    ``(c) Waiver of Requirement of Individually Identified Patient for \nSpecified Drug Products.--\n            ``(1) Waiver authority.--The Secretary may, with respect to \n        a drug product sold or dispensed by a pharmacy or pharmacist, \n        waive the requirement of subsection (a)(1) that the drug \n        product be compounded for an individually identified patient if \n        the Secretary determines that compounding the drug product is \n        necessary--\n                    ``(A) to address a drug shortage; or\n                    ``(B) to protect public health or well-being.\n            ``(2) Duration.--The duration of a waiver under paragraph \n        (1) shall not exceed 1 year, unless the Secretary determines \n        that an extension is necessary to continue--\n                    ``(A) to address the drug shortage for which such \n                waiver was originally approved; or\n                    ``(B) to protect public health or well-being.\n            ``(3) Waivers by states prohibited.--The Secretary may not \n        authorize any State to grant waivers under this subsection.\n    ``(d) Waiver of Requirement of Individually Identified Patient for \nSpecified Pharmacies and Pharmacists.--\n            ``(1) Waiver authority.--The Secretary may waive the \n        requirement of subsection (a)(1) that the drug product be \n        compounded for an individually identified patient if the \n        pharmacy or pharmacist--\n                    ``(A) submits an application that meets the \n                requirements of paragraph (5)(A) and is satisfactory to \n                the Secretary (or, subject to paragraph (3), the \n                State); and\n                    ``(B) agrees to comply with any condition of \n                operation and any limitations specified by the \n                Secretary as a requirement for such waiver, including \n                the conditions and limitations specified under \n                paragraph (5).\n            ``(2) Ineligible pharmacies.--A pharmacy or pharmacist \n        required to be registered under section 510 for purposes of \n        compounding a drug product is not eligible for a waiver under \n        this subsection for such purposes.\n            ``(3) Types of pharmacies eligible for waiver.--Subject to \n        paragraph (2), the Secretary shall specify types of pharmacies \n        and pharmacists that are eligible for a waiver under this \n        subsection, and shall include the following types:\n                    ``(A) Any pharmacy or pharmacist within a hospital \n                system that is compounding drug products exclusively \n                for dispensing to patients within that hospital system.\n                    ``(B) Any pharmacy or pharmacist that compounds \n                sterile drug products.\n                    ``(C) Any pharmacy or pharmacist that compounds \n                drug products in limited quantities before the receipt \n                of a valid prescription for an individual patient who \n                is located in the same State as the pharmacy or \n                pharmacist, based on a history of the pharmacy or \n                pharmacist receiving such valid prescription.\n            ``(4) Waivers by states allowed.--\n                    ``(A) Memorandum of understanding.--The Secretary \n                may authorize a State to grant waivers under paragraph \n                (1) to pharmacies and pharmacists in such State \n                pursuant to a memorandum of understanding entered into \n                between the Secretary and the State--\n                            ``(i) ensuring, to the Secretary's \n                        satisfaction, that the State's program for \n                        granting waivers will be implemented in \n                        accordance with the requirements of this \n                        section (including the application of different \n                        requirements for different types of pharmacies, \n                        as specified under paragraph (5)(B)); and\n                            ``(ii) including such other information and \n                        assurances as the Secretary may require.\n                    ``(B) Determination.--The Secretary shall establish \n                criteria and a process for determining whether to \n                authorize a State to grant waivers under paragraph (1).\n                    ``(C) Scope of authorization.--In authorizing a \n                State to grant waivers under subparagraph (A), the \n                Secretary may limit such authority to apply only with \n                respect to certain types of pharmacies and pharmacists \n                specified under paragraph (3).\n                    ``(D) Limitation.--A waiver granted by a State to a \n                pharmacy or pharmacist under subparagraph (A) shall \n                only apply with respect to compounded drug products \n                sold or dispensed within such State.\n            ``(5) Applications; requirements.--\n                    ``(A) In general.--For each type of pharmacy or \n                pharmacist specified under paragraph (3), the Secretary \n                shall specify, in the regulations under subsection (j), \n                the following:\n                            ``(i) The information that is required to \n                        be included in an application for a waiver \n                        under paragraph (1).\n                            ``(ii) The circumstances necessary to \n                        support the approval of such an application by \n                        the Secretary, or by a State that is authorized \n                        to grant waivers under paragraph (4), including \n                        the criteria that shall be used to evaluate \n                        such an application.\n                            ``(iii) The conditions of operation, \n                        including good manufacturing practices and \n                        requirements for third-party testing, \n                        applicable to the compounding of drugs under \n                        such a waiver.\n                            ``(iv) Any limitations on the activities \n                        that a pharmacy or pharmacist may engage in \n                        under such a waiver.\n                            ``(v) The duration (and renewability) of \n                        such a waiver.\n                    ``(B) Specificity to types of pharmacies and \n                pharmacists.--In establishing requirements under \n                subparagraph (A), the Secretary shall make the \n                requirements specific to each type of pharmacy and \n                pharmacist specified by the Secretary under paragraph \n                (3).\n    ``(e) Waiver of Requirement Regarding Copies of Commercially \nAvailable Drug.--\n            ``(1) Waiver authority.--The Secretary may, with respect to \n        a drug product sold or dispensed by a pharmacy or pharmacist, \n        waive the requirement of subsection (a)(7) if the Secretary \n        determines that compounding the drug product is necessary to \n        protect public health or well-being.\n            ``(2) Duration.--The duration of a waiver under paragraph \n        (1) shall not exceed 1 year, unless the Secretary determines \n        that an extension is necessary to protect public health or \n        well-being.\n            ``(3) Waivers by states prohibited.--The Secretary may not \n        authorize any State to grant waivers under this subsection.\n    ``(f) Inspections.--The facilities of any pharmacy or pharmacist \ncompounding drug products pursuant to a waiver under subsection (c), \n(d), or (e) shall be subject to inspection under section 704 for \npurposes of determining compliance with the provisions of this Act \napplicable to such compounding.\n    ``(g) Cancellation of Waiver.--\n            ``(1) In general.--The Secretary shall publish notice at \n        least 30 days before cancelling a waiver under subsection (c), \n        (d), or (e).\n            ``(2) Exception for public health and safety.--The \n        Secretary may cancel a waiver without regard to paragraph (1) \n        in order to prevent an adverse impact on public health or \n        safety.\n    ``(h) Labeling.--The labeling of any drug product compounded \npursuant to subsection (a) shall include the following statement: `This \ndrug has not been tested for safety and effectiveness and is not \napproved by the FDA. Serious adverse reactions to this drug should be \nreported to the pharmacy where it was received and the FDA at _____.' \nThe blank shall specify a phone number and a Web site, to be provided \nby the Secretary for purposes of this subsection.\n    ``(i) Reporting by Pharmacists and Physicians.--\n            ``(1) Adverse event.--If a pharmacist or physician \n        compounding a drug product pursuant to this section becomes \n        aware of any adverse event associated with the use of such \n        product, not later than 10 calendar days after becoming so \n        aware, the pharmacist or physician shall report such adverse \n        event to the Secretary.\n            ``(2) Information related to risk of injury or death.--If a \n        pharmacist or physician compounding a drug product pursuant to \n        this section becomes aware of information concerning any \n        bacteriological, fungal, or other contamination; any \n        significant chemical, physical, or other change; or any \n        deterioration of a compounded drug product that has already \n        been distributed by the pharmacist or physician, that could \n        cause serious injury or death, not later than 5 calendar days \n        after becoming so aware, the pharmacist or physician shall \n        report such information to the Secretary.\n    ``(j) Regulations.--The Secretary shall promulgate regulations for \ncarrying out this section, which shall include the following:\n            ``(1) The types of pharmacies and pharmacists specified \n        pursuant to subsection (d)(3).\n            ``(2) The criteria and process for determining whether a \n        State may provide a waiver under subsection (d)(4).\n            ``(3) The information specified under subsection (d)(5)(A).\n            ``(4) The requirements applicable to different types of \n        pharmacies and pharmacists under subsection (d)(5).\n            ``(5) The requirements for inspections under subsection \n        (f).\n    ``(k) Definitions.--In this section:\n            ``(1) The term `copy of a commercially available drug \n        product' does not include a drug product in which there is a \n        change, made for an identified individual patient, which \n        produces for that patient a significant difference, as \n        determined by the prescribing practitioner, between the \n        compounded drug and the comparable commercially available drug \n        product.\n            ``(2) The term `compounding' does not include mixing, \n        reconstituting, or other such acts that are performed in \n        accordance with directions contained in approved labeling \n        provided by the product's manufacturer and other manufacturer \n        directions consistent with that labeling.''.\n    (b) Misbranding.--Section 502 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 352) is amended by adding at the end the \nfollowing:\n    ``(bb) If it is a drug product compounded pursuant to section 503A \nand its labeling does not include the statement required by section \n503A(h).''.\n    (c) Conforming Amendment.--Section 704(a)(2)(A) of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 374(a)(2)(A)) is amended by \ninserting ``subject to section 503A,'' before ``pharmacies which \nmaintain establishments''.\n    (d) Regulations.--Not later than 1 year after the date of the \nenactment of this Act, the Secretary shall promulgate final regulations \nfor carrying out the amendments made by subsections (a), (b), and (c).\n    (e) Effective Date.--The amendments made by subsections (a), (b), \nand (c) shall take effect on the date that is 1 year after the date of \nthe enactment of this Act.\n\nSEC. 3. REGISTRATION AND INSPECTION OF MANUFACTURERS COMPOUNDING DRUG \n              PRODUCTS.\n\n    (a) Registration.--Section 510(g) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 360(g)) is amended by adding at the end the \nfollowing: ``With respect to compounding drugs, the exemption in \nparagraph (1) does not apply with respect to any pharmacy to the extent \nto which the pharmacy is, in effect, manufacturing such drugs, as \ndetermined by the Secretary, taking into consideration the extent to \nwhich such pharmacy sells the drugs across State lines, the quantity of \nthe drugs sold, and any other factors determined appropriate by the \nSecretary.''.\n    (b) Inspection.--Section 704(a)(2) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 374(a)(2)) is amended by adding at the end the \nfollowing flush text:\n        ``With respect to compounding drugs, the exemption in \n        subparagraph (A) does not apply with respect to any pharmacy to \n        the extent to which the pharmacy is, in effect, manufacturing \n        such drugs, as determined by the Secretary, taking into \n        consideration the extent to which such pharmacy sells the drugs \n        across State lines, the quantity of the drugs sold, and any \n        other factors determined appropriate by the Secretary.''.\n    (c) Regulations.--Not later than 1 year after the date of the \nenactment of this Act, the Secretary of Health and Human Services shall \npromulgate regulations for carrying out the amendments made by \nsubsections (a) and (b).\n    (d) Effective Date.--The amendment made by subsection (a) shall \ntake effect on the date that is 1 year after the date of the enactment \nof this Act."
}